Histology
Carcinoma of Unknown Primary
CI-CAN-00002109Explore in graph →
4,151 active trials54 approved drugs532 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00002109Explore in graph →
Clinical trials
14,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,893)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study | withdrawn | Phase 2 | 0 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | withdrawn | Phase 1 | 0 | Brown UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Taiho Oncology, Inc.INDUSTRY | 0 | Sep 4, 2024 | clinicaltrials |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | withdrawn | Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Sep 3, 2024 | clinicaltrials |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 26, 2024 | clinicaltrials |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | withdrawn | Phase 2 | 0 | University of ChicagoOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC) | withdrawn | Phase 2 | 0 | Regeneron PharmaceuticalsINDUSTRY | 0 | Jul 26, 2024 | clinicaltrials |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 0 | Jul 25, 2024 | clinicaltrials |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma | withdrawn | Phase 2 | 0 | OHSU Knight Cancer InstituteOTHER | 1 | Jul 19, 2024 | clinicaltrials |
| NCT06357858 | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | withdrawn | Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT05572476 | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer(LURBIMUNE) | withdrawn | Phase 2 | 0 | Institut BergoniéOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT06057636 | Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study | withdrawn | N/A | 0 | The University of Tennessee, KnoxvilleOTHER | 1 | May 10, 2024 | clinicaltrials |
| NCT04614766 | A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors(SPORE-3) | withdrawn | Phase 1 / Phase 2 | 0 | David BushnellOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT05412875 | Pilot Trial of E Cigarettes in Pts Diagnosed With Cancer of the Head, Neck, and Lung | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05390021 | PET/MRI in Endometrial Cancer | withdrawn | N/A | 0 | Massachusetts General HospitalOTHER | 0 | Apr 2, 2024 | clinicaltrials |
| NCT04731740 | Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer | withdrawn | Phase 2 | 0 | Saint Petersburg State University, RussiaOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT05967286 | Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Mar 20, 2024 | clinicaltrials |
| NCT05472506 | Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck Cancer | withdrawn | Phase 1 | 0 | Ikena OncologyINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04140513 | Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer | withdrawn | N/A | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 8, 2024 | clinicaltrials |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Hansoh BioMedical R&D CompanyINDUSTRY | 0 | Mar 4, 2024 | clinicaltrials |
| NCT05156372 | Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients(HIIT PCa) | withdrawn | N/A | 0 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05474690 | A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer | withdrawn | Phase 3 | 0 | Henan Cancer HospitalOTHER_GOV | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05292443 | Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer | withdrawn | — | 0 | Geneplus-Beijing Co. Ltd.INDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT01913275 | Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy | withdrawn | N/A | 0 | All India Institute of Medical SciencesOTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT04760288 | A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC) | withdrawn | Phase 3 | 0 | Hoffmann-La RocheINDUSTRY | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04756505 | Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial | withdrawn | Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 27, 2023 | clinicaltrials |
| NCT03494803 | Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMC | withdrawn | — | 0 | HKGepitherapeuticsINDUSTRY | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer | withdrawn | Early Phase 1 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Dec 22, 2023 | clinicaltrials |
| NCT04892875 | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers(PANTHEoN) | withdrawn | Phase 1 | 0 | Jennifer ChoeOTHER | 0 | Nov 30, 2023 | clinicaltrials |
| NCT00657332 | Clinical and Pathologic Studies in Neuroendocrine Tumors | withdrawn | — | 0 | Stanford UniversityOTHER | 0 | Nov 28, 2023 | clinicaltrials |
| NCT05641922 | Safety and Effectiveness of BioTraceIO 360 for Planning, Monitoring and Assessment of Liver Tissue Ablation Procedures (PANORAMA2)(PANORAMA2) | withdrawn | N/A | 0 | Techsomed Medical Technologies LTDINDUSTRY | 0 | Nov 27, 2023 | clinicaltrials |
| NCT04555603 | Axitinib Therapy Management Study | withdrawn | — | 0 | PfizerINDUSTRY | 1 | Nov 21, 2023 | clinicaltrials |
| NCT04602117 | ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer | withdrawn | Phase 1 | 0 | QuantumLeap Healthcare CollaborativeOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | withdrawn | Phase 2 | 0 | Sumitomo Pharma America, Inc.INDUSTRY | 0 | Nov 14, 2023 | clinicaltrials |
| NCT05111314 | Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma | withdrawn | Early Phase 1 | 0 | Mayo ClinicOTHER | 1 | Nov 7, 2023 | clinicaltrials |
| NCT04054752 | Vaccine Response With NT-I7 | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05161533 | Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05436808 | Partial Chest Wall Radiation Therapy After Surgery for Lymph Node Negative Breast Cancer | withdrawn | Early Phase 1 | 0 | Stony Brook UniversityOTHER | 1 | Oct 18, 2023 | clinicaltrials |
| NCT05032079 | Subzero and Scorpion Trial | withdrawn | N/A | 0 | Larkin Community HospitalOTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03875053 | Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer | withdrawn | N/A | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05371860 | Radiation Omission in Patients With HER2 Overexpressing Tumors With Pathologic Complete Response | withdrawn | Phase 2 | 0 | Armando GiulianoOTHER | 1 | Sep 22, 2023 | clinicaltrials |
| NCT05359692 | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | Incyte Biosciences International SàrlINDUSTRY | 1 | Sep 15, 2023 | clinicaltrials |
| NCT04834349 | Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT05535023 | Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 13, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2024source: clinicaltrials